Non-small Cell Lung Cancer Clinical Trials in Guangzhou, Guangdong
52 recruitingGuangzhou, Guangdong, China
Showing 1–20 of 52 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled215 locationsNCT06345729
Recruiting
Phase 2
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 2Phase 3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Alpha Biopharma (Jiangsu) Co., Ltd.800 enrolled34 locationsNCT07143045
Recruiting
Phase 2
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
MRDNSCLC (Non-small Cell Lung Cancer)II-IIIB Stages+1 more
Guangdong Association of Clinical Trials115 enrolled2 locationsNCT07120698
Recruiting
Phase 2
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Non-small Cell Lung Cancer
Dizal Pharmaceuticals90 enrolled4 locationsNCT06295432
Recruiting
Phase 2
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.300 enrolled1 locationNCT07229729
Recruiting
Phase 3
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
Non-small Cell Lung CancerCardiovascular Complication
Sun Yat-sen University524 enrolled1 locationNCT04980716
Recruiting
Phase 2
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.121 enrolled16 locationsNCT05956587
Recruiting
Phase 1Phase 2
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.98 enrolled1 locationNCT06114511
Recruiting
Phase 3
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University311 enrolled3 locationsNCT07052669
Recruiting
Phase 3
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
NSCLC (Non-small Cell Lung Cancer)
Guangdong Provincial People's Hospital70 enrolled1 locationNCT07016126
Recruiting
Phase 2
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Non-small Cell Lung Cancer (NSCLC)
Sun Yat-sen University83 enrolled1 locationNCT06977074
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Non-small Cell Lung CancerKRAS P.G12C
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205
Recruiting
Phase 3
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.500 enrolled1 locationNCT06671379
Recruiting
Phase 2
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
Non-small Cell Lung Cancer MetastaticEGFR G719XEGFR L861Q+1 more
Sun Yat-sen University23 enrolled1 locationNCT06517953
Recruiting
Phase 1
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.250 enrolled5 locationsNCT06403735
Recruiting
Phase 2
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Non-small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.110 enrolled2 locationsNCT05351788
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Non-small Cell Lung Cancer (NSCLC)EGFR-TKI Resistant MutationEGFR-TKI Sensitizing Mutation+2 more
Sun Yat-sen University1,000 enrolled1 locationNCT01994057